Powered by

-Moleculin Biotech Reports Year Ended December 31, 2017 Financial Results

Apr 02, 2018 - ENP Newswire
Board and Executive Moves-Financial Results

HOUSTON - Moleculin Biotech, Inc. (NASDAQ: MBRX) ('Moleculin' or the 'Company'), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced its financial results for the year ended December 31, 2017.

Additionally, the Company announced potential upcoming milestones and recent corporate developments.